<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33398802</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Building a Case for Withaferin A as a Treatment for FTD/ALS Syndromes.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>285</EndPage><MedlinePgn>284-285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-020-00991-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borchelt</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-0813-6979</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida College of Medicine, McKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA. drb1@ufl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054358">Withanolides</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6DO3QW4K5</RegistryNumber><NameOfSubstance UI="C009684">withaferin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054358" MajorTopicYN="Y">Withanolides</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33398802</ArticleId><ArticleId IdType="pmc">PMC8116393</ArticleId><ArticleId IdType="doi">10.1007/s13311-020-00991-7</ArticleId><ArticleId IdType="pii">10.1007/s13311-020-00991-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mukherjee PK, Banerjee S, Biswas S, Das B, Kar A, Katiyar CK. Withania somnifera (L.) Dunal - Modern perspectives of an ancient Rasayana from Ayurveda. J Ethnopharmacol. 2021;264:113157. doi: 10.1016/j.jep.2020.113157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.113157</ArticleId><ArticleId IdType="pubmed">32783987</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl T, Sharma A, Sharma L, Sehgal A, Zengin G, Brata R, et al. Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives. Biomedicines. 2020;8:E571. doi: 10.3390/biomedicines8120571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8120571</ArticleId><ArticleId IdType="pmc">PMC7762146</ArticleId><ArticleId IdType="pubmed">33291236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Phaneuf D, Julien J-P. Withaferin-A Treatment Alleviates TAR DNA-Binding Protein-43 Pathology and Improves Cognitive Function in a Mouse Model of FTLD. Neurother J Am Soc Exp Neurother. United States; 2020;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116414</ArticleId><ArticleId IdType="pubmed">33078279</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Julien J-P, Kriz J. Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurother J Am Soc Exp Neurother. 2015;12:217&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322065</ArticleId><ArticleId IdType="pubmed">25404049</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupr&#xe9; N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B-mediated pathogenic pathways. J Exp Med. 2011;208:2429&#x2013;47. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta K, Patel P, Rahimian R, Phaneuf D, Julien J-P. Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration. Neurother J Am Soc Exp Neurother. 2017;14:447&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5398980</ArticleId><ArticleId IdType="pubmed">27928708</ArticleId></ArticleIdList></Reference><Reference><Citation>Logie E, Vanden BW. Tackling Chronic Inflammation with Withanolide Phytochemicals-A Withaferin a Perspective. Antioxidants (Basel, Switzerland) 2020;9:1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7696210</ArticleId><ArticleId IdType="pubmed">33182809</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahiruddin S, Basist P, Parveen A, Parveen R, Khan W, Gaurav, et al. Ashwagandha in brain disorders: A review of recent developments. J Ethnopharmacol. 2020;257:112876. doi: 10.1016/j.jep.2020.112876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2020.112876</ArticleId><ArticleId IdType="pubmed">32305638</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai T, Jiang W, Guo Z, Wang Z, Huang M, Zhong G, et al. Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q-TRAP. Biomed Chromatogr. 2019;33:e4573. doi: 10.1002/bmc.4573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bmc.4573</ArticleId><ArticleId IdType="pubmed">31062367</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>